Recommendation ID
IPG559/1
Question

NICE encourages further research on transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine. Data should be collected for all patients not entered into controlled trials. Studies should describe clearly whether the procedure is used for treatment or prevention. They should include details of patient selection and the dose and frequency of use. Outcome measures should include the number and severity of migraine episodes, quality of life in the short and long term and any changes in medication. The development of any complications after starting treatment should be documented. NICE may update the guidance on publication of further evidence.

Any explanatory notes
(if applicable)

Current evidence on transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine raises no major safety concerns. The evidence on efficacy is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent and audit or research.


Source guidance details

Comes from guidance
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine
Number
IPG559
Date issued
May 2016

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 31/05/2016